Stuttering as the first sign of CAR-T-cell-related encephalopathy syndrome (CRES)

J Cancer Res Clin Oncol. 2019 Jul;145(7):1917-1918. doi: 10.1007/s00432-018-2818-y. Epub 2018 Dec 11.

Authors

L Nicolas Gonzalez Castro¹, Jorg Dietrich², Deborah A Forst²

Affiliations

¹ Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital Cancer Center, 55 Fruit Street Yawkey Center Suite 9E, Boston, MA, 02114, USA. lgonzalez-castro@mgh.harvard.edu.
² Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital Cancer Center, 55 Fruit Street Yawkey Center Suite 9E, Boston, MA, 02114, USA.

PMID: 30539279
DOI: 10.1007/s00432-018-2818-y

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antigens, CD19 / adverse effects
Antigens, CD19 / therapeutic use*
Biological Products
Brain Diseases / diagnosis*
Brain Diseases / etiology
Female
Humans
Immunotherapy, Adoptive / adverse effects*
Lymphoma, Large B-Cell, Diffuse / immunology
Lymphoma, Large B-Cell, Diffuse / therapy*
Neurotoxicity Syndromes / diagnosis*
Neurotoxicity Syndromes / etiology
Prognosis
Receptors, Chimeric Antigen / immunology*
Stuttering / physiopathology*
T-Lymphocytes / immunology*

Substances

Antigens, CD19
Biological Products
Receptors, Chimeric Antigen
axicabtagene ciloleucel